Mark Cohen

Practice areas

Intellectual Property, Technology Transactions

Focus areas

Patents, Science and Technology Law

Mark Cohen, a founder and senior partner at the law firm of Pearl Cohen Zedek Latzer Baratz, represents a diverse clientele that spans from startup ventures to Fortune 500 corporations. His primary focus within his legal practice centers on intellectual property matters, including patent licensing and litigation, intellectual property transactions and management, and the drafting and negotiation of agreements.

In 1989, Mr. Cohen earned a Bachelor of Arts in biochemistry from Rutgers, The State University of New Jersey, followed by a Master of Science in biology from New York University in 1990. He later obtained a Juris Doctor from The University of Baltimore School of Law in 1993.

Mr. Cohen’s expertise extends to helping clients effectively manage and capitalize on their intellectual property assets. He offers his assistance to entrepreneurs, startup companies, private enterprises, and multinational corporations, providing services such as due diligence assessments, patentability opinions, licensing arrangements, opposition proceedings, and validity assessments in a wide range of industries, including pharmaceuticals, energy, semiconductors, electronics, life sciences, medical technology, automotive, defense, and aerospace. Mr. Cohen is admitted to the New York State Bar Association and the U.S. Patent and Trademark Office.

In addition to his legal work, Mr. Cohen places a strong emphasis on his involvement in the legal community. He frequently shares his knowledge and experience through lectures delivered to various professional organizations. His contributions also include publishing articles in prestigious publications like the Nature Biotechnology journal and several patent trade journals.

Outside of his legal commitments, Mr. Cohen has served on the board of MaSTherCell, which was later acquired by Catalant, Inc. He has previously held positions as chairman of the board and chairman of the governance and nominating committee for Akari Therapeutics and Tarus Therapeutics, Inc.